FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration - PubMed (original) (raw)
doi: 10.1007/s00401-010-0698-6. Epub 2010 May 20.
Keith A Josephs, Jonathan D Rohrer, Ian R Mackenzie, Manuela Neumann, Astrid Authier, Harro Seelaar, John C Van Swieten, Jeremy M Brown, Peter Johannsen, Jorgen E Nielsen, Ida E Holm; FReJA Consortium; Dennis W Dickson, Rosa Rademakers, Neill R Graff-Radford, Joseph E Parisi, Ronald C Petersen, Kimmo J Hatanpaa, Charles L White 3rd, Myron F Weiner, Felix Geser, Vivianna M Van Deerlin, John Q Trojanowski, Bruce L Miller, William W Seeley, Julie van der Zee, Samir Kumar-Singh, Sebastiaan Engelborghs, Peter P De Deyn, Christine Van Broeckhoven, Eileen H Bigio, Han-Xiang Deng, Glenda M Halliday, Jillian J Kril, David G Munoz, David M Mann, Stuart M Pickering-Brown, Valerie Doodeman, Gary Adamson, Shabnam Ghazi-Noori, Elizabeth M C Fisher, Janice L Holton, Tamas Revesz, Martin N Rossor, John Collinge, Simon Mead, Adrian M Isaacs
Collaborators, Affiliations
- PMID: 20490813
- PMCID: PMC2887939
- DOI: 10.1007/s00401-010-0698-6
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration
Hazel Urwin et al. Acta Neuropathol. 2010 Jul.
Abstract
Through an international consortium, we have collected 37 tau- and TAR DNA-binding protein 43 (TDP-43)-negative frontotemporal lobar degeneration (FTLD) cases, and present here the first comprehensive analysis of these cases in terms of neuropathology, genetics, demographics and clinical data. 92% (34/37) had fused in sarcoma (FUS) protein pathology, indicating that FTLD-FUS is an important FTLD subtype. This FTLD-FUS collection specifically focussed on aFTLD-U cases, one of three recently defined subtypes of FTLD-FUS. The aFTLD-U subtype of FTLD-FUS is characterised clinically by behavioural variant frontotemporal dementia (bvFTD) and has a particularly young age of onset with a mean of 41 years. Further, this subtype had a high prevalence of psychotic symptoms (36% of cases) and low prevalence of motor symptoms (3% of cases). We did not find FUS mutations in any aFTLD-U case. To date, the only subtype of cases reported to have ubiquitin-positive but tau-, TDP-43- and FUS-negative pathology, termed FTLD-UPS, is the result of charged multivesicular body protein 2B gene (CHMP2B) mutation. We identified three FTLD-UPS cases, which are negative for CHMP2B mutation, suggesting that the full complement of FTLD pathologies is yet to be elucidated.
Similar articles
- The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS, Hu Q, Rollinson S, Halliwell N, Robinson A, Davidson YS, Momeni P, Baborie A, Griffiths TD, Jaros E, Perry RH, Richardson A, Pickering-Brown SM, Neary D, Mann DM. Snowden JS, et al. Acta Neuropathol. 2011 Jul;122(1):99-110. doi: 10.1007/s00401-011-0816-0. Epub 2011 Mar 20. Acta Neuropathol. 2011. PMID: 21424531 - Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A, Rozemuller AJ, van Swieten JC. Seelaar H, et al. J Neurol. 2010 May;257(5):747-53. doi: 10.1007/s00415-009-5404-z. Epub 2009 Nov 28. J Neurol. 2010. PMID: 19946779 Free PMC article. - RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
Hofmann JW, Seeley WW, Huang EJ. Hofmann JW, et al. Annu Rev Pathol. 2019 Jan 24;14:469-495. doi: 10.1146/annurev-pathmechdis-012418-012955. Epub 2018 Oct 24. Annu Rev Pathol. 2019. PMID: 30355151 Free PMC article. Review. - Frontotemporal lobar degeneration: diversity of FTLD lesions.
Seilhean D, Bielle F, Plu I, Duyckaerts C. Seilhean D, et al. Rev Neurol (Paris). 2013 Oct;169(10):786-92. doi: 10.1016/j.neurol.2013.07.015. Epub 2013 Sep 12. Rev Neurol (Paris). 2013. PMID: 24035575 Review.
Cited by
- A 44-year-old man with profound behavioural changes.
Laforce R Jr, Kerchner GA, Rabinovici GD, Fong JC, Miller BL, Seeley WW, Grinberg LT. Laforce R Jr, et al. Can J Neurol Sci. 2012 Jul;39(4):527-30. doi: 10.1017/s0317167100014086. Can J Neurol Sci. 2012. PMID: 22728864 Free PMC article. No abstract available. - Clinicopathologic differences among patients with behavioral variant frontotemporal dementia.
Mendez MF, Karve SJ, Tassniyom K, Teng E, Shapira JS. Mendez MF, et al. Neurology. 2013 Feb 5;80(6):561-8. doi: 10.1212/WNL.0b013e3182815547. Epub 2013 Jan 16. Neurology. 2013. PMID: 23325909 Free PMC article. - Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease.
Boxer AL, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J, Hellmuth J, Trojanowski JQ, Huang E, DeArmond S, Neuhaus J, Miller BL. Boxer AL, et al. Arch Neurol. 2012 Apr;69(4):509-17. doi: 10.1001/archneurol.2011.1021. Arch Neurol. 2012. PMID: 22491196 Free PMC article. - Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration.
Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C. Lang CM, et al. J Biol Chem. 2012 Jun 1;287(23):19355-65. doi: 10.1074/jbc.M112.365098. Epub 2012 Apr 17. J Biol Chem. 2012. PMID: 22511793 Free PMC article. - Prion-like propagation as a pathogenic principle in frontotemporal dementia.
Hock EM, Polymenidou M. Hock EM, et al. J Neurochem. 2016 Aug;138 Suppl 1(Suppl Suppl 1):163-83. doi: 10.1111/jnc.13668. J Neurochem. 2016. PMID: 27502124 Free PMC article. Review.
References
- Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919. doi: 10.1038/nature05016. - DOI - PubMed
- Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, Al Sarraj S, King A, Scahill R, Warren JD, Fox NC, Rossor MN, Collinge J, Mead S. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain. 2008;131:706–720. doi: 10.1093/brain/awm320. - DOI - PMC - PubMed
- Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology. 2004;63:1376–1384. - PMC - PubMed
- Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL, III, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171:227–240. doi: 10.2353/ajpath.2007.070182. - DOI - PMC - PubMed
- Cairns NJ, Uryu K, Bigio EH, Mackenzie IRA, Gearing M, Duyckaerts C, Yokoo H, Nakazato Y, Jaros E, Perry RH, Arnold SE, Lee VMY, Trojanowski JQ. alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 2004;108:213–223. doi: 10.1007/s00401-004-0882-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MC_U123160657/MRC_/Medical Research Council/United Kingdom
- P01 AG017586/AG/NIA NIH HHS/United States
- NS65782-01 J/NS/NINDS NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- G0701441/MRC_/Medical Research Council/United Kingdom
- UL1RR024982/RR/NCRR NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- G0601846/MRC_/Medical Research Council/United Kingdom
- R01 NS065782/NS/NINDS NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P50 AG16574/AG/NIA NIH HHS/United States
- 089701/WT_/Wellcome Trust/United Kingdom
- G0801306/MRC_/Medical Research Council/United Kingdom
- AG10124/AG/NIA NIH HHS/United States
- P30 AG13854/AG/NIA NIH HHS/United States
- AG17546/AG/NIA NIH HHS/United States
- MC_U123182015/MRC_/Medical Research Council/United Kingdom